{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:14:44Z","timestamp":1772853284224,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jpsychires.2020.06.011","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T17:30:31Z","timestamp":1594315831000},"page":"160-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis"],"prefix":"10.1016","volume":"129","author":[{"given":"Masaki","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Asami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia B.","family":"Wajsbrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Pappadopulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2020.06.011_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987"},{"key":"10.1016\/j.jpsychires.2020.06.011_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.jpsychires.2020.06.011_bib3","series-title":"Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"issue":"4","key":"10.1016\/j.jpsychires.2020.06.011_bib4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/ijnp\/pyz003","article-title":"Venlafaxine ER blocks the norepinephrine transporter in the brain of patients with major depressive disorder: a PET study using [18F]FMeNER-D2","volume":"22","author":"Arakawa","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.jpsychires.2020.06.011_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/acps.13001","article-title":"How to choose an antidepressant medication","volume":"139","author":"Bayes","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2020.06.011_bib6","first-page":"1","article-title":"Rating scales for affective disorders: their validity and consistency","volume":"295","author":"Bech","year":"1981","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"2","key":"10.1016\/j.jpsychires.2020.06.011_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.31887\/DCNS.2006.8.2\/pbech","article-title":"Rating scales in depression: limitations and pitfalls","volume":"8","author":"Bech","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"issue":"Suppl. 2","key":"10.1016\/j.jpsychires.2020.06.011_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4088\/JCP.12084su1c.04","article-title":"Neurotransmitter targeting in the treatment of depression","volume":"74","author":"Blier","year":"2013","journal-title":"J. Clin. Psychiatr."},{"issue":"4","key":"10.1016\/j.jpsychires.2020.06.011_bib9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamapsychiatry.2017.0025","article-title":"Reevaluating the efficacy and predictability of antidepressant treatments: a symptom clustering approach","volume":"74","author":"Chekroud","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"10128","key":"10.1016\/j.jpsychires.2020.06.011_bib10","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"1-2","key":"10.1016\/j.jpsychires.2020.06.011_bib11","first-page":"115","article-title":"Factor analysis of the Hamilton depression scale","volume":"1","author":"Cleary","year":"1977","journal-title":"Drugs Exp. Clin. Res."},{"issue":"3","key":"10.1016\/j.jpsychires.2020.06.011_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/10401239709147791","article-title":"Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group","volume":"9","author":"Cunningham","year":"1997","journal-title":"Ann. Clin. Psychiatr."},{"issue":"1","key":"10.1016\/j.jpsychires.2020.06.011_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1017\/S1461145705006413","article-title":"Differential physiological effects of a low dose and high doses of venlafaxine in major depression","volume":"10","author":"Debonnel","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jpsychires.2020.06.011_bib15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nm.4246","article-title":"Resting-state connectivity biomarkers define neurophysiological subtypes of depression","volume":"23","author":"Drysdale","year":"2017","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.jpsychires.2020.06.011_bib16","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1176\/ajp.2006.163.7.1161","article-title":"A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report","volume":"163","author":"Fava","year":"2006","journal-title":"Am. J. Psychiatr."},{"issue":"7","key":"10.1016\/j.jpsychires.2020.06.011_bib17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","article-title":"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis","volume":"6","author":"Furukawa","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.jpsychires.2020.06.011_bib18","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archgenpsychiatry.2011.2044","article-title":"Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine","volume":"69","author":"Gibbons","year":"2012","journal-title":"Arch. Gen. Psychiatr."},{"issue":"8","key":"10.1016\/j.jpsychires.2020.06.011_bib19","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0149-2918(03)80210-2","article-title":"Venlafaxine: a 2003 update","volume":"25","author":"Gutierrez","year":"2003","journal-title":"Clin. Therapeut."},{"issue":"5","key":"10.1016\/j.jpsychires.2020.06.011_bib20","article-title":"Functional recovery in major depressive disorder: focus on early optimized treatment","volume":"18","author":"Habert","year":"2016","journal-title":"Prim. Care Companion CNS Disord"},{"issue":"1","key":"10.1016\/j.jpsychires.2020.06.011_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/YIC.0000000000000105","article-title":"A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan","volume":"31","author":"Higuchi","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2020.06.011_bib23","first-page":"97","article-title":"Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder","volume":"89","author":"Kato","year":"2017","journal-title":"A sequential RCT. J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2020.06.011_bib24","first-page":"94","article-title":"Early symptom change prediction of remission in depression treatment","volume":"42","author":"Katz","year":"2009","journal-title":"Psychopharmacol. Bull."},{"issue":"3","key":"10.1016\/j.jpsychires.2020.06.011_bib25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/0269881119896066","article-title":"Effects of desvenlafaxine versus placebo on MDD symptom clusters: a pooled analysis","volume":"34","author":"Katzman","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jpsychires.2020.06.011_bib26","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1097\/00004714-199606002-00005","article-title":"Dose-response relationship with venlafaxine","volume":"16","author":"Kelsey","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.jpsychires.2020.06.011_bib27","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatr."},{"issue":"1","key":"10.1016\/j.jpsychires.2020.06.011_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004714-199802000-00004","article-title":"The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group","volume":"18","author":"Khan","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2020.06.011_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-244X-8-3","article-title":"Evaluating dose response from flexible dose clinical trials","volume":"8","author":"Lipkovich","year":"2008","journal-title":"BMC Psychiatr."},{"issue":"3","key":"10.1016\/j.jpsychires.2020.06.011_bib30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/YIC.0000000000000256","article-title":"Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity","volume":"34","author":"Lyndon","year":"2019","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2-3","key":"10.1016\/j.jpsychires.2020.06.011_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000111537","article-title":"Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)","volume":"56","author":"Mallinckrodt","year":"2007","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jpsychires.2020.06.011_bib32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"issue":"1-3","key":"10.1016\/j.jpsychires.2020.06.011_bib33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jad.2013.01.020","article-title":"Which somatic symptoms are associated with an unfavorable course in Asian patients with major depressive disorder?","volume":"149","author":"Novick","year":"2013","journal-title":"J. Affect. Disord."},{"issue":"Suppl. E1","key":"10.1016\/j.jpsychires.2020.06.011_bib34","first-page":"e08","article-title":"International consensus statement on major depressive disorder","volume":"71","author":"Nutt","year":"2010","journal-title":"J. Clin. Psychiatr."},{"issue":"2","key":"10.1016\/j.jpsychires.2020.06.011_bib35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ijnp\/pyx081","article-title":"Functional recovery in major depressive disorder: providing early optimal treatment for the individual patient","volume":"21","author":"Oluboka","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.jpsychires.2020.06.011_bib36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4088\/JCP.v59n0305","article-title":"A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression","volume":"59","author":"Rudolph","year":"1998","journal-title":"J. Clin. Psychiatr."},{"issue":"2-3","key":"10.1016\/j.jpsychires.2020.06.011_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0165-0327(99)00067-1","article-title":"A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression","volume":"56","author":"Rudolph","year":"1999","journal-title":"J. Affect. Disord."},{"issue":"11","key":"10.1016\/j.jpsychires.2020.06.011_bib39","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatr."},{"issue":"1","key":"10.1016\/j.jpsychires.2020.06.011_bib40","first-page":"244S","article-title":"Once-daily extended release (XR) venlafaxine versus paroxetine in outpatients with major depression [abstract 90-49]","volume":"42","author":"Salinas","year":"1997","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2020.06.011_bib42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jpsychires.2014.02.001","article-title":"Depression symptom clusters and their predictive value for treatment outcomes: results from an individual patient data meta-analysis of duloxetine trials","volume":"53","author":"Schacht","year":"2014","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2020.06.011_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/JCP.v60n0105","article-title":"Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group","volume":"60","author":"Silverstone","year":"1999","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2020.06.011_bib45","series-title":"Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Application","author":"Stahl","year":"2013"},{"issue":"2","key":"10.1016\/j.jpsychires.2020.06.011_bib46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/03007995.2016.1255185","article-title":"A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg\/day for the treatment of major depressive disorder","volume":"33","author":"Thase","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"issue":"9","key":"10.1016\/j.jpsychires.2020.06.011_bib47","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4088\/JCP.v58n0904","article-title":"Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group","volume":"58","author":"Thase","year":"1997","journal-title":"J. Clin. Psychiatr."},{"issue":"1","key":"10.1016\/j.jpsychires.2020.06.011_bib49","doi-asserted-by":"crossref","first-page":"14082","DOI":"10.1038\/s41598-018-32521-z","article-title":"Identification of depression subtypes and relevant brain regions using a data-driven approach","volume":"8","author":"Tokuda","year":"2018","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.jpsychires.2020.06.011_bib50","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.4088\/JCP.v66n0816","article-title":"Symptom clusters as predictors of late response to antidepressant treatment","volume":"66","author":"Trivedi","year":"2005","journal-title":"J. Clin. Psychiatr."},{"issue":"6","key":"10.1016\/j.jpsychires.2020.06.011_bib51","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1176\/appi.ajp.2012.12020250","article-title":"Increase in work productivity of depressed individuals with improvement in depressive symptom severity","volume":"170","author":"Trivedi","year":"2013","journal-title":"Am. J. Psychiatr."},{"issue":"5","key":"10.1016\/j.jpsychires.2020.06.011_bib52","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1017\/S0033291711001905","article-title":"Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms","volume":"42","author":"Uher","year":"2012","journal-title":"Psychol. Med."},{"issue":"9","key":"10.1016\/j.jpsychires.2020.06.011_bib53","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/da.22233","article-title":"Major depressive disorder subtypes to predict long-term course","volume":"31","author":"van Loo","year":"2014","journal-title":"Depress. Anxiety"},{"issue":"10","key":"10.1016\/j.jpsychires.2020.06.011_bib54","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1017\/S0033291709005182","article-title":"Course and outcome of depressive disorders in primary care: a prospective 18-month study","volume":"39","author":"Vuorilehto","year":"2009","journal-title":"Psychol. Med."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395620308438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395620308438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:17:20Z","timestamp":1758367040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395620308438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":48,"alternative-id":["S0022395620308438"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2020.06.011","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2020.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}